Program
romosozumab
Also written as “Romosozumab”, “Romozosumab” and “romosozumab HCP administration with PFS”.
Its studies are mostly in Osteoporosis, Postmenopausal · Osteoporosis · Bone Diseases, Metabolic · Osteogenesis Imperfecta · Hip Fractures, led by 2 companies.
Drug pageRomosozumab: every studyAll 39 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgenits history only | 212 open or running | phase 4since Sep 25, 2023 | May 7, 2009 | Jan 14, 2027phase 1 · NCT07811999 |
| UCB | 10 open or running | phase 3since Sep 23, 2021 | Sep 23, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of UCB only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 23, 2021First study: phase 3 study in OsteoporosisFirst studyNCT05067335 · 327 enrolled · China
TargetBeta
“Sclerostin inhibitor”ChEMBL 37, by rule
Studies
The one study UCB leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05067335Osteoporosis · China | 3 | Completed | Nov 9, 2023 | 327 |
How it is read
Names in the registry
- “Romosozumab”, 19 entries
- “Romozosumab”, 1 entry
- “romosozumab HCP administration with PFS”, 1 entry
- “Romosozumab 90 mg/mL”, 1 entry
- “Romosozumab 70 mg/mL”, 1 entry
Conditions, from the studies’ own filings
- Osteoporosis, Postmenopausal, 8 studies
- Osteoporosis, 5 studies
- Bone Diseases, Metabolic, 4 studies
- Osteogenesis Imperfecta, 2 studies
- Hip Fractures, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.